IMMUNeOCT Study: The Role of Octreotide LAR in Modulating the Immune Response in Patient with Neuroendocrine Tumors. EudraCT Number 2017-001613-83
Introduction: SSAs are used in the treatment of G1/G2 Neuroendocrine Neoplasms (NEN) in order to control symptoms and induce tumor shrinkage with an excellent tolerability profile. The role of immune response is crucial in defining the clinical response to treatment through the active stimulation of effector cells (T and NK cells) but also through the inhibition of tumor-induced immune suppression. The immune regulatory cells CD4-CD25-expressing Tregs and myeloid cellsMDSC can contribute to disease progression through various mechanisms.
Aim(s): The study aims to evaluate the impact of Octreotide LAR in modulating the immune regulatory cells in patient with NENs.
Materials and methods: At the NCI of Naples, Italy, a single-arm perspective study started. Octreotide LAR 30 mg will be administered accordingly with SmPC. Treg and MDSC in the peripheral blood tumor and in peritumoral area of NEN patients treated with Octreotide LAR will be performed at baseline time and during the treatment through flow cytometry. MDSC and Treg cells will be identified by specific surface receptors. The suppressive activity of Tregs will be assessed by evaluating the proliferation of CFSE-labeled Teff cell by Facs analysis.
Conference: 15th Annual ENETSConcerence (2018)
To read the full abstract, please log into your ENETS Member account.